Login / Signup

Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis.

Lauren StroberJohn DeLucaRalph Hb BenedictAdam JacobsJeffrey A CohenNancy D ChiaravallotiLynn D HudsonRichard A RudickNicholas G LaRoccanull null
Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2018)
Consistent with the published literature, the SDMT proved superior to the PASAT. The SDMT should be considered the measure of choice for MS trials in assessing cognitive processing speed.
Keyphrases
  • multiple sclerosis
  • clinical trial
  • white matter
  • systematic review
  • phase ii
  • mild cognitive impairment
  • open label
  • study protocol
  • double blind
  • meta analyses
  • phase iii